Sinew Pharma Inc. (6634.TWO)
TWD 47.0
(1.51%)
TWD 47.0
(1.51%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | - | 328 Thousand | 6.22 Million | 462 Thousand | - |
| Cost of Revenue | 28.98 Million | 38 Thousand | 1.13 Million | 138 Thousand | - |
| Gross Profit | -28.98 Million | 290 Thousand | 5.09 Million | 324 Thousand | - |
| Operating Expenses | 186.25 Million | 148.71 Million | 99.51 Million | 84.43 Million | 76.84 Million |
| Selling, General and Administrative Expenses | 34.74 Million | 34.1 Million | 26.76 Million | 17.72 Million | 16.55 Million |
| Research and Development Expenses | 133.45 Million | 114.61 Million | 72.74 Million | 66.7 Million | 60.29 Million |
| Other Expenses | - | 150 Thousand | 40 Thousand | 2000.00 | 10 Thousand |
| Cost and Expenses | 186.25 Million | 148.75 Million | 100.64 Million | 84.56 Million | 76.84 Million |
| Operating Income | -186.25 Million | -139.9 Million | -91.42 Million | -81.73 Million | -76.04 Million |
| Interest Expense | - | 275 Thousand | 146 Thousand | 274 Thousand | 176 Thousand |
| Income Tax Expense | - | - | - | - | - |
| Earnings before Tax | -170.92 Million | -140.18 Million | -91.57 Million | -82.01 Million | -76.22 Million |
| Net Income | -170.92 Million | -140.18 Million | -91.57 Million | -82.01 Million | -76.22 Million |
| Earnings Per Share Basic | -2.43 | -2.02 | -1.54 | -1.60 | -1.94 |
| Earnings Per Share Diluted | -2.43 | -2.02 | -1.54 | -1.60 | -1.94 |
| Weighted Average Shares Outstanding | 70.33 Million | 69.29 Million | 59.49 Million | 51.29 Million | 39.37 Million |
| Weighted Average Shares Outstanding (Diluted) | 70.46 Million | 69.29 Million | 59.49 Million | 51.29 Million | 39.37 Million |
| Gross Margin | - | 0.88 | 0.82 | 0.70 | - |
| EBIT Margin | - | -356.99 | -11.04 | -129.61 | - |
| Profit Margin | - | -427.38 | -14.70 | -177.51 | - |
| EBITDA | -163.63 Million | -117.09 Million | -68.78 Million | -59.88 Million | -57.79 Million |
| Earnings Before Tax Margin | - | -426.54 | -14.68 | -176.92 | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | 15.18 Million | - | - | - | - | - |
| Gross Profit | -15.18 Million | - | - | - | - | - |
| Operating Expenses | 41.75 Thousand | 41.75 Thousand | 56.67 Thousand | 56.67 Thousand | 36.44 Thousand | 36.44 Thousand |
| Selling, General and Administrative Expenses | 9453.00 | 9453.00 | 9204.50 | 9204.50 | 8169.00 | 8169.00 |
| Research and Development Expenses | 32.3 Thousand | 32.3 Thousand | 47.47 Thousand | 47.47 Thousand | 28.28 Thousand | 28.28 Thousand |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | 41.75 Thousand | 41.75 Thousand | 56.67 Thousand | 56.67 Thousand | 36.44 Thousand | 36.44 Thousand |
| Operating Income | -41.75 Thousand | -41.75 Thousand | -56.67 Thousand | -56.67 Thousand | -36.44 Thousand | -36.44 Thousand |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | - | - | - | - | - | - |
| Earnings before Tax | -36.93 Thousand | -36.93 Thousand | -52.3 Thousand | -52.3 Thousand | -33.15 Thousand | -33.15 Thousand |
| Net Income | -36.93 Thousand | -36.93 Thousand | -52.3 Thousand | -52.3 Thousand | -33.15 Thousand | -33.15 Thousand |
| Earnings Per Share Basic | -0.00 | -0.52 | -0.74 | -0.74 | -0.48 | -0.48 |
| Earnings Per Share Diluted | -0.00 | -0.52 | -0.74 | -0.74 | -0.48 | -0.47 |
| Weighted Average Shares Outstanding | 71.03 Million | 71.03 Million | 70.82 Million | 70.82 Million | 69.57 Million | 69.8 Million |
| Weighted Average Shares Outstanding (Diluted) | 71.3 Million | 71.3 Million | 70.88 Million | 70.88 Million | 69.8 Million | 70.04 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -35.77 Thousand | -35.77 Thousand | -50.75 Thousand | -50.75 Thousand | -31.05 Thousand | -31.05 Thousand |
| Earnings Before Tax Margin | - | - | - | - | - | - |
PANW
CDTAF
FEDFINA
MNPR
CCNEP
TMUS